Can Test Reports Be Reused for Malaysia MDA Medical Device Registration?

Short answer: In most cases, test reports prepared for NMPA, CE, FDA or other markets cannot be reused verbatim for Malaysia MDA medical device registration. They can serve as a reusable evidence base, but their acceptability depends on the product classification and registration pathway under Malaysia's Medical Device Act 2012 (Act 737) and MDA requirements, the conformity assessment standards applied, the accreditation status and scope of the testing laboratory, the model and specification coverage of each report, and whether the report remains valid and consistent with the technical file. Companies should therefore complete a product classification and documentation gap assessment first, then decide which reports can be carried over, which must be supplemented or re-issued, and which must be reformatted into the target-country submission structure.

Key Summary

Documentation for Malaysia MDA medical device registration is usually built around product classification, the technical file, ISO 13485 quality system evidence, performance verification, risk management, clinical evaluation or clinical evidence, labelling and instructions for use, authorization documents, and the appointment of a local representative. Companies should complete a documentation gap assessment before deciding whether existing NMPA, CE or other market material can be reused.

For Chinese medical device manufacturers, the more reliable approach is to confirm product classification and complete a gap assessment first, and only then determine whether NMPA, CE, FDA, ISO 13485 or other market documentation can be reused. Target-market registration typically affects the technical file, authorized representative arrangements, importer cooperation, labelling language, quality system evidence and subsequent change control at the same time. If a project is driven only by a list of "documents to submit", deficiencies and rework are likely to appear in model coverage, evidence chain consistency, label claims and certificate control.

AIMEILI recommends positioning this question within a broader GHWP member state and multi-country market access strategy: use one reusable core technical file to support localization in different markets, rather than rebuilding documentation from scratch for each country.

This content is compiled from the AIMEILI regulatory practice question bank, the AIMEILI medical device international registration knowledge base and publicly available regulatory information. Specific projects should be based on the latest requirements of the target-country regulator and the underlying product documentation.

Applicable Scenarios and Core Questions

Companies searching for "can test reports be reused for Malaysia medical device registration" are usually not looking for a conceptual explanation. They need to judge whether existing documentation can support a target-market submission, whether a local agent or authorized representative is required, why the timeline is being extended, and which issues could affect the launch plan. Behind this question there are usually several connected topics: product classification, registration pathway, evidence chain, labelling localization and post-market maintenance responsibilities.

If a company plans to enter several GHWP member states at the same time, or markets in Southeast Asia, the Middle East and Latin America, answering the process for one country alone is not enough. A more valuable approach is to first build reusable versions of the core technical file, quality system evidence, performance verification, clinical evidence and labelling, and then localize them according to each country's regulatory requirements.

Registration Decision Logic

Companies should first confirm the intended use, mechanism of action, use scenario, body contact type, duration of use, sterility, whether the device is active, and whether it contains software or has IVD characteristics. Only then can the risk class and submission pathway be determined. If the pathway is wrong, all subsequent translation, notarization, authorization, testing and supplementary submissions will move in the wrong direction.

For a target-market project, the applicant entity and the boundaries of local responsibility must also be confirmed: who holds the certificate, who handles regulatory communication, who manages importation and post-market events, who triggers changes, and who maintains renewal documentation. If these points are left vague in a commercial contract, market control can easily be affected later.

Documents and Evidence

Typical documentation includes the product description, model and specification matrix, intended use, risk classification rationale, ISO 13485 or applicable quality system evidence, the technical file, performance verification reports, risk management documentation, clinical evaluation or clinical evidence, labelling and instructions for use, authorization documents, existing registration certificates, manufacturer declarations and post-market surveillance documentation.

The key to documentation quality is not volume but consistency. Instructions-for-use claims, the models covered by test reports, the scope of clinical evidence, risk management conclusions, label warnings and the information in the registration application form must support one another. Regulators focus on whether the device is safe, effective and traceable for its intended use, not on how many files have been uploaded.

Common Mistakes

• Treating registration as a simple document submission without clarifying product classification, evidence coverage and local responsibility relationships first.
• Translating NMPA documentation and submitting it directly, without re-arranging the evidence according to the target-market pathway.
• Having too many models and specifications while test reports, clinical evidence or labels cover insufficient scope.
• Selecting a local agent purely on the basis of sales cooperation, without defining regulatory responsibility, certificate control and post-market maintenance duties.
• Inconsistency between labels, instructions for use, promotional material and registration documentation claims, leading to deficiency notices or post-market compliance risk.
• Failing to plan multi-country documentation reuse in advance, resulting in duplicated preparation for each country and inflated cost and timelines.

Company Preparation Checklist

Before starting a project, companies are advised to use an internal checklist to confirm the documentation base, so that critical evidence gaps are not discovered only after submission.

• Compile the target product list, model and specification matrix, and intended use statements.
• Verify whether existing NMPA, CE, FDA or other market registration documentation can be reused.
• Prepare the ISO 13485 certificate, test reports, risk management documentation, clinical evaluation and English instructions for use.
• Confirm the responsibilities, fees, certificate control and exit mechanism of the local agent or authorized representative.
• Build a target-country gap assessment table that identifies what must be re-tested, translated, notarized or supported by supplementary declarations.

AIMEILI Perspective

AIMEILI advises companies not to treat target-market registration as a one-off document submission, but to manage it as an overseas market access programme. For companies entering multiple countries, establishing a clear core technical file and evidence matrix first and then converting it to national requirements is usually faster, more stable and more conducive to subsequent changes and certificate renewals than supplementing documentation on an ad hoc basis for each country.

From a project management perspective, three things should be controlled as early as possible: first, product classification and pathway determination; second, the consistency of the documentation evidence chain; third, the regulatory responsibility boundaries of local partners. If these three items are not clear, a project may still face repeated rounds of deficiency responses, agent communication and post-market maintenance, even when the documentation appears substantial.

Project Execution Recommendations

When executing this type of registration project, companies should maintain a project ledger covering the product list, models and specifications, registration pathway, document owners, translation status, testing status, local agent communication records and expected submission dates in a single table. This makes documentation gaps visible quickly and helps management judge whether the project will affect the launch plan.

Companies that already hold registrations in several countries should also build an evidence reuse matrix, clarifying which documents can serve as core evidence and which must be re-issued or supplemented for specific countries. Labelling and instructions for use, clinical evaluation, risk management, performance verification and quality system certificates must in particular remain version-consistent.

• Confirm the target market and product list.
• Complete risk classification and pathway determination.
• Build a documentation gap assessment table.
• Define the local agent and certificate control arrangements.
• Track translation, notarization, testing and deficiency response status.
• Arrange post-market maintenance responsibilities in advance.

Quality System and Evidence Consistency

From a registration review perspective, quality system documentation is not an isolated certificate. Regulators typically examine whether the manufacturer name, manufacturing address, product scope, certificate validity, applicable standards and technical file are mutually consistent. If the scope of the ISO 13485 certificate does not match the submitted products, or if the manufacturing address, model and specification, or instructions-for-use version differs from the test reports, additional clarification may be required even when a large volume of documents has been prepared.

Before submission, companies should build an evidence consistency checklist that maps the product name, models and specifications, intended use, applicable standards, test report numbers, clinical evaluation conclusions, risk management version, labelling and instructions-for-use version, and quality system certificate item by item. This step appears basic, but it can significantly reduce the probability of deficiency notices, particularly for projects submitted simultaneously in multiple GHWP member states or covering multiple product families.

Localization and Representative Responsibilities

Target-market registration projects usually involve a local agent, authorized representative, importer or registration holder arrangement. Companies need to confirm in advance whether the local partner is responsible only for submitting documents, or also for regulatory communication, certificate maintenance, post-market event reporting, change applications and renewal reminders. Different responsibility boundaries directly affect certificate control and subsequent market stability.

Labelling, instructions for use and authorization documents also cannot be handled by simple translation. Companies should verify local language requirements, the boundaries of product claims, warnings, storage and transport conditions, UDI or traceability requirements, importer information, authorized representative information and after-sales contact details. For companies that already hold CE, FDA, NMPA or other market documentation, the focus of localization is converting reusable evidence into a submission structure acceptable in the target country, not writing an isolated set of documents again.

Post-Market Maintenance and Long-Term Planning

Registration is not the end of compliance work. Companies also need to maintain certificate validity, change records, distributor authorizations, complaint handling, adverse event reporting, recall procedures, label versions and regulatory update records. Many companies invest heavily in obtaining the certificate but neglect post-market maintenance, so that a change of manufacturing address, an expansion of models, an update to instructions for use or a change of agent later leaves the certificate disconnected from actual market sales.

AIMEILI recommends managing this issue within an annual international registration plan: first define target-market priorities, then build a reusable documentation package and a country gap list, and finally schedule submission, deficiency response, post-market maintenance and renewal milestones. The value is not only higher efficiency for a single country, but also the development of a repeatable overseas compliance capability that reduces the cost of rebuilding documentation every time a new market is entered.

Frequently Followed-Up Questions

Can domestic Chinese registration documents be used directly for target-market registration?

Domestic Chinese documentation can serve as a foundation, but it normally cannot be submitted as it stands. Companies need to adjust the document structure, language, labelling, authorization documents and evidence chain according to local regulatory requirements.

When is the best time to start a gap assessment?

The gap assessment should start as soon as the target market and product list are confirmed. The earlier it is completed, the easier it is to arrange supplementary testing, translation, label adjustment and agent selection in advance.

Why does the choice of local agent affect registration quality?

The local agent typically participates in registration communication, changes, renewals and post-market event handling. If responsibilities are unclear, certificate control and subsequent market stability can be affected.

Continued Reading

Previous article: How Should Clinical Evaluation Documentation Be Prepared for Malaysia MDA Medical Device Registration?

Next article: How Is an ISO 13485 Certificate Used in Malaysia MDA Medical Device Registration?

Recommended Reading

• How should registration documentation be prepared for Malaysia MDA medical device registration?
• How is product classification determined for Malaysia MDA medical device registration?
• How should the technical file be organized for Malaysia MDA medical device registration?
• How should labelling and instructions for use be localized for Malaysia MDA medical device registration?
• How should clinical evaluation documentation be prepared for Malaysia MDA medical device registration?
• How is an ISO 13485 certificate used in Malaysia MDA medical device registration?

Return to the FAQ Centre | News and Insights | Contact AIMEILI

Content Review and Scope of Application

Content author: AIMEILI Regulatory Editorial Team. Professional review: AIMEILI Medical Device International Registration Project Team.

Source principle: priority is given to official regulatory authorities, international organizations, standards organizations and publicly available regulatory materials; industry media and project experience are used only as supporting reference.

Scope of application: this article is intended for preliminary understanding, documentation preparation and project planning. It does not replace the formal requirements of the target-country regulator, testing conclusions or legal advice.

Published: 10 July 2026 09:20; Updated: 10 July 2026 09:20.